Zilico receives funding to develop the diagnostic device for oral cancer

Zilico receives funding to develop the diagnostic device for oral cancer -

Zilico Ltd began its development work on a medical device that uses electrical impedance spectroscopy (EIS) in the detection and diagnosis of cancer oral Technology Strategy Board funding, the innovation agency of the United Kingdom.

both prices are Feasibility of Biomedical Catalyst funding and smart. The funds will help support a thorough analysis of the UK market, providing a specification for an oral diagnostic device and a protocol for a multi-center trial.

The funding builds on proven concept-study that was recently introduced and is part of a wider development program leading to a multi-center trial. The awards will help support development projects worth £ 0k.

flagship Zilico ZedScan EIS uses its proprietary technology to detect dysplasia and cervical cancer. Oral cancer following neoplastic way similar to the cervix, DIE can be used to detect changes in oral epithelium cells progress from normal to precancerous and then cancerous.

The University of Sheffield Professor of Oral Medicine, Martin Thornhill, presented on the use of EIA in the detection and diagnosis of oral cancer and dysplasia at the most influential group of experts oral medicine in America last year.

presentation of Professor Thornhill, using impedance spectroscopy to detect potentially malignant oral lesions, was delivered at the 67th Annual Meeting of the American Academy of Oral Medicine (AAOM) in San Antonio, Texas . The study on 50 patients was the result of a collaboration between the University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust and Zilico Ltd.

The summary of the presentation was published in the oral surgery, oral pathology, oral medicine and oral Radiology Journal in September 2013. The full paper describing the study has been accepted for publication in the Journal Nanomedicine

Zilico chief Sameer Kothari said :.

We are delighted to have secured this funding which will allow us to build on the proof of concept study and positive feedback received data to the AAOM last year.

we are now well positioned to further develop the device and evaluate in a multi-center clinical study. There is a clear clinical need for accurate diagnosis in the patient's course.